BRAF and metastatic neoplasm: A recent consensus guideline was published by the International Hepato-Pancreato-Biliary Association (IHPBA), identifying that patients with non-resectable CRLM without extrahepatic metastatic disease or high-risk molecular criteria (BRAF V600E mutation, microsatellite stable, and mismatch repair proficient) who have shown a response to either 3 months of chemotherapy or 6 months of bridging therapy may be eligible for LT [20].